Candida dubliniensis in a Brazilian family with an HIV 1- infected child: Identification, antifungal susceptibility, drug accumulation and sterol composition

Brazilian Journal of Microbiology

Volumn 37, Issue 3, 2006, Pages 237-243

  De Melo, Nadja Rodrigues ^a,b   Taguchi, Hideaki ^c   Culhari, Vitoria V P ^b   Sano, Ayako ^b   Fukushima, Kazutaka ^b   Miyaji, Makoto ^c   Manning, Nigel ^d   Kelly, Steven L ^a   Vilela, M Marluce S ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c CHIBA UNIVERSITY   (Japan)

^d SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Antifungal agents; Candida dubliniensis; Sterol composition

Indexed keywords

CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33845908202     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822006000300008     Document Type: Article

References (29)

1. Beighton, D.; Ludford, R.; Clark, D.T.; Bailsford, S.R.; Pankhurst, C.L.; et al. Use of CHROMagar Candida medium for isolation of yeasts from dental samples. J. Clin. Microbiol., 33, 3025, 1995.
2. Biswas, S.K.; Yokohama, K.; Wang, L.; Nishimura, K.; Miyaji, M. Identification of Candida dubliniensis based on the specific amplification of mitochondrial cytochrome b gene. Nippon Ishinkin Gakkai Zasshi, 42(2), 95, 2001.
3. Buurman, E.T.; Blodgett, A.E.; Hull, K.G.; Carcanague, D. Pyridines and pyrimidines mediating activity against an efflux-negative strain of Candida albicans through putative inhibition of lanosterol demethylase. Antimicrob. Agents Chemother., 48, 313, 2004.
4. Coleman, D.C.; Sullivan, D.J.; Bennett, D.E.; Moran, G.P.; Barry, H.J.; Shanley, D.B. Candidiasis: the emergence of a novel species, Candida dubliniensis. Aids, 11, 557, 1997.
5. Jackson, C.J.; Lamb, D.C.; Manning, N.J.; Kelly, D.E.; Kelly, S.L. Mutations in Saccharomyces cerevisiae sterol C5-desaturase conferring resistance to the CYP51 inhibitor fluconazole. Biochem. Biophys. Res. Commun., 309, 999, 2003.
6. Joseph-Horne, T.; Loeffler, R.S.; Hollomon, D.W.; Kelly, S.L. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J. Med. Vet. Mycol., 34, 223, 1996.
7. Karababa, M.; Coste, A.T.; Rognon, B.; Bille, J.; Sanglard, D. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob. Agents Chemother., 48, 3064, 2004.
8. Kelly, S.L.; Lamb, D.C.; Kelly, D.E.; Loeffler, J.; Einsele, H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet, 348, 1523, 1996.
9. Kelly, S.L.; Lamb, D.C.; Kelly, D.E.; Manning, N.J.; Loeffler, J.; et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 400: 80, 1997.
10. Mariano, P. de L.; Milan, E.P.; da Matta, D.A.; Colombo, A.L. Candida dubliniensis identification in Brazilian yeast stock collection. Mem. Inst. Oswaldo Cruz, 98, 533, 2003.
11. Milan, E.P.; de Laet Sant' Ana, P.; de Azevedo Melo, A.S.; Sullivan, D.J.; Coleman, D.C.; et al. Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients. Diagn. Microbiol. Infect. Dis., 41, 29, 2001.
12. Milan, E.P.; Kallas, E.G.; Costa, P.R.; da Matta, D.A.; Lopes Colombo, A. Oral colonization by Candida spp. among AIDS household contacts. Mycoses, 44, 273, 2001.
13. Moran, G.P.; Sullivan, D.J.; Henman, M.C.; McCreary, C.E.; Harrington, B.J. et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother, 41, 617, 1997.
14. Muller, F.M.; Groll, A.H.; Walsh, T.J. Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. Eur. J. Pediatr., 158, 187, 1999.
15. National Committee for Clinical Laboratory Standards (NCCLS). National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. Wayne, Pa, 1997.
16. Nguyen, M.H.P.J.; Jr. Morris, A.J.; Tanner, D.C.; Nguyen, M.L.; Snydman D.R.; et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med., 100, 617, 1996.
17. Perea, S.; Lopez-Ribot, J.L.; Kirkpatrick, W.R.; McAtee, R.K.; Santillan, R.A.; et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 45, 2676, 2001.
18. Pfaller, M.A.; Messer, S.A.; Gee, S.; Joly, S.; Pujol, C.; et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol., 37, 870, 1999.
19. Pinjon, E.; Moran, G.P.; Jackson, C.J.; Kelly, S.L.; Sanglard, D.; et al. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother., 47, 2424, 2003.
20. Rodero, L.; Losso, M.; Canteros, C.; Hochenfellner, F.; Davel, G.. [Candida dubliniensis: 1st isolation in Argentina]. Rev. Argent. Microbiol., 30, 39, 1998.
21. Sandven, P. Laboratory identification and sensitivity testing of yeast isolates. Acta Odontol. Scand., 48, 27, 1990.
22. Sanglard, D.; Kuchler, K.; Ischer, F.; Pagani, J.L.; Monod, M.; Bille, J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother., 39, 2378, 1995.
23. Sano, A.; Vilela, M.M.; Takahashi, I.; Fukushima, K.; Takizawa, K.; et al. Isolation of Candida dubliniensis from the oral cavity of an HIV-positive child in Brazil. Nippon Ishinkin Gakkai Zasshi, 41, 177, 2000.
24. Schorling, S.R.; Kortinga, H.C.; Froschb, M.; Muhlschlegel, F.A. The role of Candida dubliniensis in oral candidiasis in human immunodeficiency virus-infected individuals. Crit. Rev. Microbiol., 26, 59, 2000.
25. Soll, D.R. High-frequency switching in Candida albicans. Clin. Microbiol. Rev., 5, 183, 1992.
26. Sullivan, D.J.; Westerneng, T.J.; Haynes, K.A.; Bennett, D.E; Coleman, D.C. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology, 141 (Pt 7), 1507, 1995.
27. Sullivan S.; Coleman D. Candida dubliniensis: characteristics and identification. J. Clin. Microbiol., 36, 1998.
28. Tsuchiya T. Serological characterization. Methods Microbiol., 16, 26, 1980.
29. Vilela, M.M.; Kamei, K.; Sano, A.; Tanaka, R.; Uno, J.; et al. Pathogenicity and virulence of Candida dubliniensis: comparison with C. albicans. Med. Mycol., 40, 249, 2002.